2ONE Labs Prevails in Trademark Dispute against IMB Zone Brand

Business by 2FIRSTS.ai
Dec.24.2024
2ONE Labs Prevails in Trademark Dispute against IMB Zone Brand
US nicotine pouch brand 2ONE Labs wins preliminary injunction in trademark dispute with Imperial Tobacco's Zone brand.

On December 23rd, the American nicotine pouch brand 2ONE Labs announced on its official website that the brand, in partnership with distributor Performance Plus Marketing, had achieved a favorable preliminary injunction (PI) ruling in a trademark dispute with the Imperial Tobacco brand Zone. According to a court order dated December 20th, 2024, Zone's nicotine pouches are prohibited from being shipped to trade partners in the United States.

 

The CEO of 2ONE Labs, Vincent Schuman, stated that

 

This ruling is significant as it prohibits Imperial Tobacco from continuing to sell Zone nicotine pouches in the United States until the ongoing 2ONE trademark lawsuit is resolved.

 

According to the judge's ruling, the defendant (Imperial) is prohibited from selling oral nicotine products with the Bullseye trademark or any similar symbol. (Case number: CV 24-08124-MWF(Ex) Title: 2ONE Labs Inc. et al v. ITG Brands, LLC et al)

 

We are pleased that the court has made the correct decision to approve this PI. This is an extraordinary remedy for 2ONE and sets the foundation for their victory in the trademark infringement lawsuit against Imperial Tobacco.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Patent Reveals China Tobacco Hubei Industrial Testing Animal Model for Heated Tobacco Safety Evaluation
Patent Reveals China Tobacco Hubei Industrial Testing Animal Model for Heated Tobacco Safety Evaluation
China Tobacco Hubei Industrial Co., Ltd. has published a patent describing a laboratory method to evaluate the reproductive and developmental safety of heated tobacco products using non-human animal exposure models. The approach introduces a structured toxicological testing framework that could support safety verification, quality control, and regulatory evidence generation for heated tobacco products.
Mar.09
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska’s attorney general has sent warning letters to more than 1,500 retailers and distributors, cautioning them against selling tobacco products — including e-cigarettes and oral nicotine pouches — that lack U.S. Food and Drug Administration authorization.
Mar.06 by 2FIRSTS.ai
Geekvape Launches New E-cigarette "KLOUD" with Unique Oil Refill and Cartridge Swapping Features
Geekvape Launches New E-cigarette "KLOUD" with Unique Oil Refill and Cartridge Swapping Features
GEEKVAPE launches new e-cigarette KLOUD, featuring hybrid design for oil filling and cartridge swapping, priced at $7.49.
Apr.01 by 2FIRSTS.ai
Arizona Lawmaker Pushes Alternative Nicotine Product Bill as Enforcement Concerns Emerge
Arizona Lawmaker Pushes Alternative Nicotine Product Bill as Enforcement Concerns Emerge
Arizona Representative Jeff Weninger’s HB 4001 is being presented as a new tool to crack down on retailers that sell vaping devices and other nicotine products to minors. The bill would create a licensing system for manufacturers and distributors of “alternative nicotine products” and impose fines for sales to people under 21, with penalties reaching USD 10,000 for a fourth violation within 24 months.
Mar.25 by 2FIRSTS.ai
California Bill Would Let Schools Include Nicotine in Student-Athlete Drug Screens
California Bill Would Let Schools Include Nicotine in Student-Athlete Drug Screens
California lawmakers are advancing a bill that would allow schools with existing student-athlete drug testing programs to include nicotine in those screenings.
Apr.09 by 2FIRSTS.ai
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
2Firsts has learned that France’s national health authority, the Haute Autorité de Santé (HAS), confirmed the role of e-cigarettes will be addressed in updated national smoking-cessation guidelines expected by the end of 2026. HAS said the recommendations will focus on clinical and public-health considerations, will not set technical standards for vaping products, and that current studies are insufficient to clearly assess risks and benefits across different product categories.
Mar.10